Novartis Pharmaceuticals – Acute Lymphoblastic Leukemia

Access Program Information

This is a single arm, open-label, multi-center, phase II study to determine the safety and
efficacy of CTL019 in pediatric/young adult patients with r/r B-cell ALL.